China Biotechnology Industry 2025: Gene Therapy, mRNA Vaccines, CDMO and Innovation Pipeline
China's biotechnology industry has undergone a transformative shift from generic drug manufacturing to innovative drug discovery and development. The National Medical Products Administration (NMPA) has accelerated drug approval processes, reducing average review times by over forty percent since 2017. Chinese companies now lead in CAR-T cell therapy, gene editing research and novel mRNA platform development, while CDMO giants like WuXi Biologics serve global pharmaceutical clients from facilities across China, Ireland and the United States.
TL;DR
China hosts over 1,800 active clinical trials, making it the second-largest clinical research market globally. Domestic CAR-T cell therapies have received NMPA approval, and multiple Chinese mRNA vaccine platforms are in advanced trials. The CDMO sector, led by WuXi Biologics, generated over USD 20 billion in revenue in 2024 serving international clients.
Key Insights
Active Clinical Trials
China has over 1,800 active clinical trials across oncology, immunology, rare diseases and infectious diseases, making it the second-largest clinical trial market after the United States.
CDMO Revenue
Chinese CDMO companies, led by WuXi Biologics and Pharmaron, generated over USD 20 billion in 2024, providing drug development and manufacturing services to the world's top twenty pharmaceutical firms.
CAR-T Approvals
Five domestic CAR-T cell therapy products have received NMPA approval, with several additional candidates in Phase II/III trials for hematological malignancies and solid tumors.
NMPA New Drug Approvals 2024
The NMPA approved over eighty new molecular entities and biologics in 2024, including first-in-class drugs from Chinese companies, reflecting faster review pathways and improved clinical data quality.
Side-by-Side Comparison
| Metric | China | USA | EU | Japan |
|---|---|---|---|---|
| Active clinical trials | 1,800+ | 9,000+ | 5,000+ | 1,200+ |
| New drug approvals (2024) | 80+ | 60+ | 50+ | 30+ |
| CDMO revenue (USD B) | 20+ | 65+ | 25+ | 5+ |
| CAR-T approved products | 5 | 7 | 4 | 3 |
| Biotech startup funding (USD B) | 12 | 45 | 15 | 3 |
Frequently Asked Questions
Chinese CDMO firms offer lower costs, large-scale manufacturing capacity and fast project timelines. WuXi Biologics operates facilities across China, Ireland, Singapore and the US, serving global clients with end-to-end drug development services from discovery to commercial manufacturing.
Chinese companies have approved five CAR-T cell therapies domestically and are developing AAV-based gene therapies for rare diseases. Research institutions are advancing CRISPR-based therapies, with several programs in early-stage clinical trials targeting genetic blood disorders and inherited retinal diseases.
The NMPA adopted ICH guidelines, implemented priority review pathways for innovative drugs and reduced average approval times from 18 months to under 10 months. The breakthrough therapy designation accelerates access for drugs addressing unmet medical needs.
Chinese firms including Abogen, StemiRNA and Everest Medicines have developed proprietary mRNA platforms and lipid nanoparticle delivery systems. Multiple mRNA vaccines are in Phase II/III trials, and mRNA therapeutics for oncology and rare diseases are advancing through early clinical stages.